Revolutionizing the Biotech Industry: Aadi Bioscience’s Groundbreaking In-Licensing of Novel ADC Portfolio, $100 Million Sale of Fyarro, and $100 Million PIPE Financing

Aadi Enters into Exclusive License for Three-Asset ADC Portfolio Aadi Enters Agreement with KAKEN Pharmaceutical Aadi Announces PIPE Financing Aadi Bioscience, Inc. has recently made significant moves in the biopharmaceutical industry by entering into an exclusive license agreement for a three-asset portfolio of next-wave antibody-drug conjugates (ADCs). The collaboration for this portfolio was developed between…

Read More